Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
05 1월 2024 - 12:46PM
Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle
disease company focused on advancing innovative life-transforming
therapeutics for people living with genetically driven diseases,
today announced the pricing of an underwritten public offering of
17,150,000 shares of its common stock at a public offering price of
$17.50 per share. The gross proceeds to Dyne from the offering,
before deducting underwriting discounts and commissions and
offering expenses payable by Dyne, are expected to be approximately
$300.1 million. All shares in the offering are being sold by Dyne.
The offering is expected to close on or about January 9, 2024,
subject to customary closing conditions. In addition, Dyne has
granted the underwriters a 30-day option to purchase up to an
additional 2,572,500 shares of its common stock at the public
offering price, less the underwriting discounts and commissions.
Morgan Stanley, J.P. Morgan, Jefferies and Stifel are acting as
joint book-running managers for the offering. Oppenheimer & Co.
and Raymond James are acting as co-managers for the offering.
The offering is being made pursuant to a shelf registration
statement on Form S-3 that was previously filed with and declared
effective by the Securities and Exchange Commission (“SEC”) and a
related registration statement that was filed with the SEC on
January 4, 2024 pursuant to Rule 462(b) under the Securities Act of
1933 (and became automatically effective upon filing). This
offering is being made only by means of a prospectus supplement and
accompanying prospectus that form a part of the registration
statements. A preliminary prospectus supplement relating to and
describing the terms of the offering has been filed with the SEC
and may be obtained for free by visiting the SEC’s website at
www.sec.gov. A final prospectus supplement relating to the offering
will be filed with the SEC. When available, copies of the final
prospectus supplement and the accompanying prospectus may also be
obtained by contacting: Morgan Stanley & Co. LLC, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY
10014, or by email at prospectus@morganstanley.com; J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204,
or by email at prospectus-eq_fi@jpmchase.com; Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by
email at Prospectus_Department@Jefferies.com; or Stifel, Nicolaus
& Company, Incorporated, Attention: Prospectus Department, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, by
telephone at (415) 364-2720 or by email at
syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases. With its
proprietary FORCE™ platform, Dyne is developing modern
oligonucleotide therapeutics that are designed to overcome
limitations in delivery to muscle tissue. Dyne has a broad pipeline
for serious muscle diseases, including clinical programs for
myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy
(DMD) and a preclinical program for facioscapulohumeral muscular
dystrophy (FSHD).
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, contained in this press
release, including statements relating to the anticipated closing
date of the public offering, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act
of 1995. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “objective,”
“ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or
“would,” or the negative of these terms, or other comparable
terminology are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Dyne may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various important
factors, including the risks and uncertainties related to the
satisfaction of customary closing conditions for the public
offering and other factors discussed in the “Risk Factors” section
of the preliminary prospectus supplement filed with the SEC on
January 3, 2024, as well as the risks and uncertainties identified
in Dyne’s filings with the SEC, including Dyne’s most recent Form
10-Q and in subsequent filings Dyne may make with the SEC. In
addition, the forward-looking statements included in this press
release represent Dyne’s views as of the date of this press
release. Dyne anticipates that subsequent events and developments
will cause its views to change. However, while Dyne may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Dyne’s views as of any date subsequent to the date of
this press release.
Contacts:
InvestorsAmy Reillyareilly@dyne-tx.com
857-341-1203
MediaStacy
Nartkersnartker@dyne-tx.com781-317-1938
Dyne Therapeutics (NASDAQ:DYN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Dyne Therapeutics (NASDAQ:DYN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024